Origin Bio

Origin Bio is a biotech company building a data engine that profiles real patient tumor tissue to predict drug response and identify biomarkers in cancer. The company addresses the problem that cancers are heterogeneous and rapidly evolving, making it difficult to determine which patients are likely to benefit from a given drug at population scale.

The data engine processes FFPE tumor blocks from hospital and biobank partners, pairing spatial transcriptomics, H&E imaging, and anonymized clinical annotations such as tumor type, grade, stage, and treatment history. From these samples, the system derives spatially resolved cell states, cell-cell interactions, pathway enrichments, and biomarkers. Retrospective and prospective cohorts are processed to train models for clinical tasks, including predicting spatial gene expression from morphology alone, predicting drug response, and identifying interpretable biomarkers. The company also lists research work on regulatory DNA, including the Axis model for generating regulatory DNA elements and predicting their function.

Origin Bio works with hospital and biobank partners supplying tissue samples and appears to serve organizations involved in oncology drug development and clinical trials. Access to the platform is requested directly through the site; no pricing, plan, or packaging details are stated.